Oncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reduced their price objective on Oncternal Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Monday.

Oncternal Therapeutics Stock Performance

Shares of Oncternal Therapeutics stock opened at $8.69 on Wednesday. Oncternal Therapeutics has a 52 week low of $5.57 and a 52 week high of $13.14. The stock has a 50 day moving average price of $8.94 and a two-hundred day moving average price of $8.11. The stock has a market capitalization of $23.38 million, a PE ratio of -0.64 and a beta of 1.26.

Oncternal Therapeutics (NASDAQ:ONCT) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($3.11) EPS for the quarter, missing analysts’ consensus estimates of ($3.09) by ($0.02). Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative return on equity of 95.87%. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.17 million. During the same period last year, the business posted ($4.00) EPS. Research analysts forecast that Oncternal Therapeutics will post -12.03 EPS for the current year.

Insider Activity at Oncternal Therapeutics

In related news, Director Robert James Wills bought 6,914 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The shares were bought at an average price of $8.48 per share, with a total value of $58,630.72. Following the completion of the transaction, the director now directly owns 6,914 shares in the company, valued at $58,630.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have purchased a total of 10,714 shares of company stock valued at $92,736 over the last 90 days. Insiders own 8.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ONCT. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Oncternal Therapeutics during the first quarter worth $585,000. Vanguard Group Inc. lifted its holdings in Oncternal Therapeutics by 9.0% during the first quarter. Vanguard Group Inc. now owns 2,325,515 shares of the company’s stock worth $3,232,000 after acquiring an additional 192,189 shares during the period. Renaissance Technologies LLC lifted its holdings in Oncternal Therapeutics by 44.4% during the first quarter. Renaissance Technologies LLC now owns 543,800 shares of the company’s stock worth $756,000 after acquiring an additional 167,268 shares during the period. Mirabella Financial Services LLP bought a new stake in Oncternal Therapeutics during the first quarter worth $38,000. Finally, UBS Group AG lifted its holdings in Oncternal Therapeutics by 1,373.8% during the second quarter. UBS Group AG now owns 166,298 shares of the company’s stock worth $184,000 after acquiring an additional 155,014 shares during the period. Hedge funds and other institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.